The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis

Objective. To evaluate the association of -174G/C IL-6 polymorphism with failure in therapeutic response to methotrexate (MTX) or leflunomide (LEF). This prospective, observational cohort included 96 Mexican-Mestizo patients with moderate or severe rheumatoid arthritis (RA), initiating MTX or LEF, g...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Padilla, A. J., Gamez-Nava, J. I., Saldaña-Cruz, A. M., Murillo-Vazquez, J. D., Vazquez-Villegas, M. L., Zavaleta-Muñiz, S. A., Martín-Márquez, B. T., Ponce-Guarneros, J. M., Rodriguez Jimenez, N. A., Flores-Chavez, A., Sandoval-Garcia, F., Vasquez-Jimenez, J. C., Cardona-Muñoz, E. G., Totsuka-Sutto, S. E., Gonzalez-Lopez, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050320/
https://www.ncbi.nlm.nih.gov/pubmed/27738630
http://dx.doi.org/10.1155/2016/4193538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050320/
https://www.ncbi.nlm.nih.gov/pubmed/27738630
http://dx.doi.org/10.1155/2016/4193538

Ejemplares similares